Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
Status:
Terminated
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out whether imaging of the prostate with a new molecule
called 68Ga-PSMA can find prostate cancer. 68Ga-PSMA has been shown in a large number of
patients to be useful to find recurring prostate cancer following initial cancer treatment.
This study is performed to test 68Ga-PSMA whether it can be used to find prostate cancers
that would be considered in need for treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center